Insert the needle at a 90-degree angle into the fat layer beneath the skin, avoiding veins or muscles
Contact your GP if lymph nodes remain swollen for more than two to four weeks, are hard or fixed, larger than 2cm, or accompanied by unexplained weight loss, night sweats, or persistent fever
a direct causal link in humans has not been established, and current EU and UK summaries of product characteristics (SmPCs) for approved GLP-1-based therapies do not list this as a formal contraindication, though it remains a theoretical concern warranting caution People with severe gastrointestinal conditions , such as gastroparesis or inflammatory bowel disease Those with a history of pancreatitis , which has been associated with GLP-1 receptor agonist use Children and young people under 18 , who have not been studied in retatrutide trials to date People with a history of gallbladder disease or gallstones , given the known association between this drug class and gallbladder events Those with proliferative diabetic retinopathy or macular oedema , where rapid improvements in blood glucose control may carry additional risks People with severe renal or hepatic impairment , pending further safety data Age-related eligibility, renal function, hepatic status, and existing medications would all need to be carefully assessed by a qualified clinician before any treatment decision could be made
GLP-1 receptor stimulation reduces amyloid- peptide accumulation and cytotoxicity in cellular and animal models of alzheimers disease
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-kidney trial
Weekly trends reveal the true trajectory
